Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EBIT (2019 - 2025)

Historic EBIT for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$114.0 million.

  • Madrigal Pharmaceuticals' EBIT rose 200.25% to -$114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$307.5 million, marking a year-over-year increase of 4389.53%. This contributed to the annual value of -$497.9 million for FY2024, which is 3084.89% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' EBIT stood at -$114.0 million, which was up 200.25% from -$47.2 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' EBIT registered a high of -$47.2 million during Q2 2025, and its lowest value of -$162.5 million during Q2 2024.
  • Its 5-year average for EBIT is -$87.1 million, with a median of -$79.3 million in 2025.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' EBIT crashed by 9408.32% in 2024, and later soared by 7095.92% in 2025.
  • Madrigal Pharmaceuticals' EBIT (Quarter) stood at -$64.6 million in 2021, then tumbled by 32.04% to -$85.3 million in 2022, then plummeted by 37.37% to -$117.2 million in 2023, then skyrocketed by 42.82% to -$67.0 million in 2024, then crashed by 70.12% to -$114.0 million in 2025.
  • Its EBIT was -$114.0 million in Q3 2025, compared to -$47.2 million in Q2 2025 and -$79.3 million in Q1 2025.